Online citations, reference lists, and bibliographies.
← Back to Search

Clinical Evaluation Of Branched DNA Signal Amplification For Quantifying HIV Type 1 In Human Plasma.

Y. Cao, D. Ho, J. Todd, R. Kokka, M. Urdea, J. Lifson, M. Piatak, S. Chen, B. Hahn, M. Saag
Published 1995 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Quantification of HIV-1 RNA in human plasma has provided unique insight into AIDS pathogenesis and promises to hasten progress in antiretroviral therapy and vaccine research. However, no generally available HIV-1 RNA assay has yet been subjected to rigorous clinical testing or to comparative evaluation with research-based RNA assays using large numbers of well-characterized clinical specimens. In this study, the Chiron Quantiplex branched DNA (bDNA) signal amplification assay was used to measure viral RNA in the plasma of 152 HIV-1-positive individuals at all stages of infection and in 12 patients before and after initiating zidovudine therapy. Eighty-six percent of patients had bDNA assay results above the 10,000-RNA Eq/ml sensitivity cutoff. Branched DNA values were significantly correlated with plasma viral RNA levels determined by quantitative competitive polymerase chain reaction (QC-PCR) assay (Spearman rank correlation, r = 0.89), infectious plasma virus titers (r = 0.72), p24 antigen levels (r = 0.51), immune complex dissociated p24 antigen levels (r = 0.56), and CD4+ lymphocyte counts (r = -0.72; p < 0.0001 for all comparisons). Plasma viral RNA determinations by bDNA and QC-PCR assays were quantitatively similar in the range of 10(4) to 10(7) RNA molecules/ml [log bDNA = 0.93 + 0.80 (log QC-PCR); R2 = 0.81, p < 0.0001] and declined identically following the institution of zidovudine therapy (68-73% decrease from baseline). The close quantitative correlation between bDNA and QC-PCR results, and their significant association with other viral markers and CD4+ counts, support the use of plasma viral RNA measurement in HIV-1 clinical trials.
This paper references
10.1126/SCIENCE.2431484
CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.
C. Walker (1986)
10.1056/NEJM198710293171804
Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia. Potential clinical importance.
J. P. Allain (1987)
10.7326/0003-4819-108-2-175
Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT).
G. G. Jackson (1988)
10.1056/NEJM198912143212401
Quantitation of human immunodeficiency virus type 1 in the blood of infected persons.
D. Ho (1989)
A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication.
C. Walker (1989)
10.7326/0003-4819-110-12-963
Predictive markers for the acquired immunodeficiency syndrome (AIDS) in hemophiliacs: persistence of p24 antigen and low T4 cell count.
M. Eyster (1989)
10.1016/0092-8674(89)90942-2
Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations
A. Meyerhans (1989)
10.1056/NEJM198912143212402
Plasma viremia in human immunodeficiency virus infection.
R. Coombs (1989)
10.1093/INFDIS/162.1.21
A simple method for improved assay demonstrates that HIV p24 antigen is present as immune complexes in most sera from HIV-infected individuals.
P. Nishanian (1990)
10.1073/PNAS.88.21.9838
Lymphoid organs function as major reservoirs for human immunodeficiency virus.
G. Pantaleo (1991)
10.1093/INFDIS/164.1.72
High-level viremia in adults and children infected with human immunodeficiency virus: relation to disease stage and CD4+ lymphocyte levels.
M. Saag (1991)
10.1056/NEJM199104043241404
High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection.
S. J. Clark (1991)
10.1056/NEJM199104043241405
Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection.
E. Daar (1991)
10.1086/190.11.2050
Detection and Qualification of Human Immunodeficiency Virus RNA in Patient Serum by Use of the Polymerase Chain Reaction
M. Holodniy (1991)
10.1016/0042-6822(92)90593-E
Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus.
S. Layne (1992)
10.1128/jvi.66.1.310-316.1992
Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease
N. Michael (1992)
10.1093/INFDIS/165.5.913
Acid dissociation increases the sensitivity of p24 antigen detection for the evaluation of antiviral therapy and disease progression in asymptomatic human immunodeficiency virus-infected persons.
R. Bollinger (1992)
10.1126/SCIENCE.1357750
Searching for markers on the AIDS trail.
J. Cohen (1992)
10.1089/AID.1992.8.47
A sensitive viral capture assay for detection of plasma viremia in HIV-infected individuals.
D. Henrard (1992)
10.1093/INFDIS/165.6.1119
Quantitation of plasma human immunodeficiency virus type 1 RNA by competitive polymerase chain reaction.
D. Scadden (1992)
10.1056/NEJM199205213262103
Detection of human immunodeficiency virus type 1 provirus in mononuclear cells by in situ polymerase chain reaction.
O. Bagasra (1992)
10.1093/INFDIS/166.2.269
Quantitation of human immunodeficiency virus provirus and circulating virus: relationship with immunologic parameters.
S. Yerly (1992)
10.1128/jvi.66.12.7328-7335.1992
Molecular profile of human immunodeficiency virus type 1 infection in symptomless patients and in patients with AIDS
P. Bagnarelli (1992)
10.1089/AID.1992.8.1263
Plasma HIV-1 viremia in HIV-1 infected individuals assessed by polymerase chain reaction.
S. Aoki-Sei (1992)
10.1128/JVI.66.11.6587-6600.1992
Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation.
Y. Li (1992)
10.1128/jvi.67.12.7423-7427.1993
High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells of HIV-1-infected chimpanzees
K. Saksela (1993)
10.1128/jcm.31.8.1980-1986.1993
Cell-free plasma human immunodeficiency virus type 1 titer assessed by culture and immunocapture-reverse transcription-polymerase chain reaction
R. Coombs (1993)
10.1128/JVI.67.4.1772-1777.1993
Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals.
R. Connor (1993)
10.1128/jcm.31.11.2960-2966.1993
Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction
M. Winters (1993)
10.1126/SCIENCE.8096089
High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.
M. Piatak (1993)
10.1038/362355A0
HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease
G. Pantaleo (1993)
10.1128/jcm.31.10.2557-2564.1993
Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee
S. Hammer (1993)
10.1016/0167-5699(93)90320-K
Lymphocyte lifespans: homeostasis, selection and competition.
A. Freitas (1993)
10.1056/NEJM199310073291502
A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase
M. Saag (1993)
10.1093/INFDIS/167.1.213
Quantification of human immunodeficiency virus type 1 tat mRNA as a marker for assessing the efficacy of antiretroviral therapy.
M. Furtado (1993)
10.1038/362359A0
Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS
J. Embretson (1993)
10.1097/00002030-199311002-00020
Qualitative and quantitative detection of HIV‐1 RNA by nucleic acid sequence‐based amplification
Bob van Gemen (1993)
10.1016/0140-6736(93)92463-4
Viral dynamics in primary HIV-1 infection
M. Piatak (1993)
10.1126/SCIENCE.8493534
Detection of HIV-1 DNA and messenger RNA in individual cells by PCR-driven in situ hybridization and flow cytometry.
B. Patterson (1993)
10.1093/CLINIDS/16.SUPPLEMENT_1.S22
Surrogate markers in AIDS clinical trials: conceptual basis, validation, and uncertainties.
S. Lagakos (1993)
10.1093/INFDIS/169.2.416
Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine.
D. Katzenstein (1994)
10.1006/VIRO.1994.1526
The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course?
S. Jurriaans (1994)
10.1073/PNAS.91.3.1104
Human immunodeficiency virus type 1 mRNA expression in peripheral blood cells predicts disease progression independently of the numbers of CD4+ lymphocytes.
K. Saksela (1994)
10.1093/INFDIS/170.3.553
Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA.
H. Lin (1994)
10.1093/INFDIS/170.5.1172
Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma.
R. Dewar (1994)
10.1128/jvi.68.8.5142-5155.1994
Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1
J. Moore (1994)
10.1128/jvi.68.4.2495-2502.1994
Dynamics of molecular parameters of human immunodeficiency virus type 1 activity in vivo
P. Bagnarelli (1994)
10.1093/INFDIS/169.4.713
Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories.
V. DeGruttola (1994)
10.1128/jcm.32.2.292-300.1994
Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection
J. Mulder (1994)
10.1038/373123A0
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
D. Ho (1995)
10.1038/373117A0
Viral dynamics in human immunodeficiency virus type 1 infection
X. Wei (1995)



This paper is referenced by
10.1007/978-981-10-4702-2_14
Novel Molecular Diagnostics and Therapeutic Tools for Livestock Diseases
S. Maan (2018)
10.1128/9781555819156.CH14
Signal Amplification Methods
Yun F. (Wayne) Wang (2016)
Enfermedades Infecciosas y Microbiología Clínica
Diego Viasus (2016)
10.1016/B978-1-4557-4801-3.00123-5
123 – The Immunology of Human Immunodeficiency Virus Infection
S. Moir (2015)
10.3892/ol.2015.3771
Quantitative analysis of cell-free DNA in ovarian cancer
Xue-feng Shao (2015)
10.1016/bs.ctdb.2015.09.002
Imaging the Cell and Molecular Dynamics of Craniofacial Development: Challenges and New Opportunities in Imaging Developmental Tissue Patterning.
L. Trinh (2015)
10.1186/1741-7015-11-147
When to start antiretroviral therapy: as soon as possible
Ricardo A. Franco (2013)
Given Zidovudine Monotherapy Resistance to Antiretroviral Drugs in Patients Methods for Quantification of Viral Load and Comparison of Culture- and Non-Culture-Based
R. Foxall (2013)
10.1016/S0213-005X(11)70027-1
Determinación de la carga viral del VIH-1
J. M. González-Alba (2011)
10.1128/9781555816834.CH35
Molecular Detection and Characterization of HIV-1
A. Caliendo (2011)
Immune activation in chronic HIV infection.
S. Ostrowski (2010)
Viral Load Test Reports
Francis Dp (2009)
10.1111/j.1365-2796.2008.02043.x
Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it?
A. Boasso (2009)
10.4049/jimmunol.0803314
Combined Effect of Antiretroviral Therapy and Blockade of IDO in SIV-Infected Rhesus Macaques1
A. Boasso (2009)
10.1007/0-387-32892-0_14
Signal Amplification Techniques: bDNA, Hybrid Capture
Y. Wang (2006)
10.1016/J.MICINF.2006.02.015
Superinfection of human immunodeficiency virus type 1 (HIV-1) to cell clone persistently infected with defective virus induces production of highly cytopathogenic HIV-1.
Yukie Iwabu (2006)
10.1007/BF01781097
Anti-V3 loop spectrotype in HIV-infected individuals during zidovudine therapy
D. R.BiselliM. (2005)
10.1038/sj.gt.3302614
Real-time quantitative PCR for the design of lentiviral vector analytical assays
C. Delenda (2005)
10.1007/BF01781103
Serum HIV-1 RNA load to predict CD4+ T-cell depletion in asymptomatic patients
D. A.LafeuilladeM. (2005)
10.1007/BF01691149
Predictive value of HIV-1 RNA detection in plasma by branched DNA assay during long-term zidovudine therapy
L. Cotte (2005)
10.1097/00126334-200312150-00011
Performance Characteristics of HIV-1 Culture and HIV-1 DNA and RNA Amplification Assays for Early Diagnosis of Perinatal HIV-1 Infection
J. Lambert (2003)
10.1006/VIRO.2001.1272
Resting CD4(+) T cells with CD38(+)CD62L(+) produce interleukin-4 which contributes to enhanced replication of T-tropic human immunodeficiency virus type 1.
H. Horikoshi (2002)
10.1182/BLOOD-2001-11-0078
Relationship of CD8(+) T cell noncytotoxic anti-HIV response to CD4(+) T cell number in untreated asymptomatic HIV-infected individuals.
JoAnn C. Castelli (2002)
10.1016/S0891-5520(01)00002-2
Molecular methods for diagnosis of infective endocarditis.
G. Lisby (2002)
10.1007/978-1-4612-2078-7_10
Bayesian Analysis of a Population HIV Dynamic Model
Cong Han (2002)
10.1097/00126334-200104010-00007
Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients.
R. Kost (2001)
10.1016/S0168-1702(00)00220-3
Differential susceptibility of resting CD4(+) T lymphocytes to a T-tropic and a macrophage (M)-tropic human immunodeficiency virus type 1 is associated with their surface expression of CD38 molecules.
H. Horikoshi (2001)
10.1128/AAC.45.5.1438-1443.2001
Short-Term Measures of Relative Efficacy Predict Longer-Term Reductions in Human Immunodeficiency Virus Type 1 RNA Levels following Nelfinavir Monotherapy
J. Mittler (2001)
10.1007/978-1-4757-4549-8_19
Rationale and Strategies for Antiretroviral Therapy in HIV-1 Infection
D. Mildvan (2001)
10.1016/S0885-3924(00)00245-1
The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: impact on medical, palliative care, and quality of life outcomes.
J. Brechtl (2001)
10.1385/MB:19:1:029
Strategies for signal amplification in nucleic acid detection
S. Andras (2001)
10.1097/00002030-200109280-00015
Early diagnosis of paediatric HIV-1 infection among African breast-fed children using a quantitative plasma HIV RNA assay
François Rouet (2001)
See more
Semantic Scholar Logo Some data provided by SemanticScholar